Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INAVAC Homologous Booster in Adults
NCT06259578Phase 1Recruiting
- Sponsor
- Dr. Soetomo General Hospital
- Start
- Jan 2024
- Primary completion
- Aug 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of salmonella typhi capsular polysaccharide vaccine in coronavirus disease 2019 (COVID-19), sponsored by Dr. Soetomo General Hospital. Primary endpoint: Humoral Immune Response at 28 days. Started Jan 2024; status: recruiting.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06259578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259578.